Paper Details

  1. Home
  2. Paper Details

Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.

Author: CroseLisa, HedrickErik, LinardicCorinne M, SafeStephen

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Panobinostat and vorinostat are histone deacetylase inhibitors. This study demonstrated the efficacy of panobinostat and vorinostat in inhibiting rhabdomyosarcoma tumor growth in vivo and inducing apoptosis in RMS cell lines. These effects were found to be due to epigenetic repression of cMyc and independent of histone acetylation.
Paper Details　
Original Abstract of the Article :
The two major types of rhabdomyosarcoma (RMS) are predominantly diagnosed in children, namely embryonal (ERMS) and alveolar (ARMS) RMS, and patients are treated with cytotoxic drugs, which results in multiple toxic side effects later in life. Therefore, development of innovative chemotherapeutic str...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26162688

データ提供：米国国立医学図書館（NLM）

HDAC Inhibitors Target Specificity Protein Transcription Factors in Rhabdomyosarcoma

Rhabdomyosarcoma (RMS) is a type of cancer that affects muscle tissue, primarily in children. This research investigates the effectiveness of histone deacetylase (HDAC) inhibitors, a class of drugs known to alter gene expression, in treating RMS.

HDAC Inhibitors Show Promise in Treating Rhabdomyosarcoma

The study found that HDAC inhibitors, panobinostat and vorinostat, effectively inhibited RMS tumor growth in laboratory studies, induced apoptosis (programmed cell death), and inhibited invasion of RMS cells. The study also identified a novel mechanism of action for these inhibitors: they target specific transcription factors, leading to changes in gene expression that ultimately inhibit RMS cell growth and survival. These findings suggest that HDAC inhibitors could be a valuable new treatment option for RMS, offering hope for improved outcomes for children with this disease.

New Insights into Rhabdomyosarcoma Treatment

This research provides valuable new insights into the mechanisms of action of HDAC inhibitors and their potential role in treating RMS. The study's findings demonstrate the complexity of cancer cell biology and the potential for targeted therapies that disrupt specific pathways involved in tumor growth and survival. Further research is needed to confirm these observations and investigate the long-term effects of HDAC inhibitors in treating RMS, but this study offers a promising path forward in the fight against this disease.

Dr. Camel's Conclusion

Just as a desert traveler relies on a compass to guide them through the intricate landscape, researchers are seeking new ways to navigate the complex world of cancer. This research sheds light on the potential of HDAC inhibitors as a new tool in the fight against rhabdomyosarcoma, offering hope for improved outcomes for young patients battling this disease.

Date :
  1. Date Completed 2016-06-07
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

26162688

DOI: Digital Object Identifier

NIHMS705358

Related Literature

Article Analysis
・Side Effects of panobinostat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.